This article is more than 5 years old. Information may no longer be current.

New AcrySof IQ ReSTOR IOL receives FDA approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland – The AcrySof IQ ReSTOR IOL (Alcon) with +3.0 D add power has been approved for cataract surgery in presbyopia patients by the U.S. Food and Drug Administration, company officials announced.

The approval arrives after clinical trials found nearly four times the number of patients achieved 20/20 or better at near, intermediate and distance with the AcrySof IQ ReSTOR +3.0 D at 3-months follow-up than those with the control lens, the AcrySof IQ ReSTOR +4.0 D.

More than 95% of patients in the clinical studies who received the AcrySof IQ ReSTOR +3.0 D lens said they would “have this lens implanted again,” Alcon officials said in a press release.

“In my experience, the AcrySof IQ ReSTOR +3.0 D add IOL gives my patients a more comfortable reading distance, improved intermediate vision for tasks such as computer work and excellent distance vision,” study investigator, Kerry Solomon, MD, said in the release.